サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514119

バイオマーカーの世界市場

Biomarkers

出版日
ページ情報
英文 413 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.02円
バイオマーカーの世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 413 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

バイオマーカーの世界市場は2030年までに2,352億米ドルに達する見込み

2023年に963億米ドルと推定されるバイオマーカーの世界市場は、2023年から2030年にかけてCAGR 13.6%で成長し、2030年には2,352億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである安全性バイオマーカーは、CAGR 13.8%を記録し、分析期間終了時には898億米ドルに達すると予測されます。有効性バイオマーカー分野の成長率は、分析期間中CAGR 12.0％と推定されます。

米国市場は249億米ドル、中国はCAGR 17.7％で成長すると予測

米国のバイオマーカー市場は2023年に249億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに578億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは17.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.4%と11.4%と予測されています。欧州では、ドイツがCAGR 10.4%で成長すると予測されています。

バイオマーカー-主要動向と促進要因のまとめ

バイオマーカーは、疾患の特定と管理のための正確なツールを提供し、治療効果を高め、新薬の開発を促進することで、ヘルスケアに革命をもたらしました。これらの生物学的指標は、様々な生物学的状態や状態を示す測定可能なシグナルであり、疾患の診断や治療効果のモニタリングに極めて重要です。当初、疾患の検出は、観察可能な身体症状とサンプル分析に大きく依存していました。しかし、長年にわたる技術の著しい進歩により、数多くのバイオマーカーが発見・開発され、医療診断や治療の選択肢が大幅に充実しました。この進化により、より早く、より正確な診断、治療戦略の改善、エラーの最小化が促進され、より良く、より費用対効果の高いヘルスケアソリューションにつながっています。

現代医療におけるバイオマーカーの統合は、病態の診断から治療結果の予測まで、様々な機能に及んでいます。それらは分子的、放射線学的、組織学的、生理学的なバイオマーカーのようなカテゴリーに分類され、それぞれがユニークな役割を担っています。例えば、分子バイオマーカーは血液や脳脊髄液のような生物学的サンプルに見られ、分子の相互作用や生化学的変化を示します。放射線学的バイオマーカーは画像検査から得られ、骨密度などの健康状態を非侵襲的に評価します。組織学的バイオマーカーは組織や細胞の生化学的変化を反映し、がんの診断や病期分類に重要です。生理学的なバイオマーカーは、血圧や心拍数のように、身体機能を直接知ることができます。これらのバイオマーカーは、診断、予後、予測、モニタリングなど、ヘルスケアの様々な段階を通して疾病管理を強化し、患者のケアや治療戦略を最適化します。

バイオマーカー分野の成長はいくつかの要因によってもたらされます。次世代シーケンシング、ハイスループットスクリーニング、バイオインフォマティクスなどの検出技術の革新により、バイオマーカー解析の精度とスピードが向上し、タイムリーで正確な診断に不可欠となっています。バイオマーカーを人工知能（AI）やビッグデータ解析と統合することで、高度なデータ解析が可能となり、疾患パターンの予測や治療成績が向上します。製薬業界では、バイオマーカーが医薬品開発プロセスを合理化し、薬物療法を個別化することで、臨床試験にかかる時間とコストを削減します。バイオマーカーを活用した先進的な診断プラットフォームは、包括的な健康評価を提供し、臨床現場での実用性を高めます。さらに、健康意識の高まりと予防医学の動向は、消費者が個別化されたヘルスケアソリューションを求めていることから、バイオマーカーの採用に影響を与えています。ヘルスケアに関する意思決定への消費者の参加の増加と、それを支援する規制の枠組みは、バイオマーカーに基づく検査と治療の使用をさらに促進します。バイオマーカー検査への保険適用が拡大することで、こうした高度な診断がより身近なものとなり、バイオマーカーが日常的な医療行為に組み込まれ、最新の医療診断と治療戦略が進展します。

調査対象企業の例（注目の合計 282社）

  • Abbott Molecular, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Epigenomics AG
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • QIAGEN NV
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-7645

Global Biomarkers Market to Reach US$235.2 Billion by 2030

The global market for Biomarkers estimated at US$96.3 Billion in the year 2023, is expected to reach US$235.2 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2023-2030. Safety Biomarkers, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$89.8 Billion by the end of the analysis period. Growth in the Efficacy Biomarkers segment is estimated at 12.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.9 Billion While China is Forecast to Grow at 17.7% CAGR

The Biomarkers market in the U.S. is estimated at US$24.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$57.8 Billion by the year 2030 trailing a CAGR of 17.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.4% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Biomarkers - Key Trends and Drivers Summarized

Biomarkers have revolutionized healthcare by providing precise tools for disease identification and management, enhancing treatment efficacy, and fostering the development of new drugs. These biological indicators are measurable signals of various biological states or conditions, crucial for diagnosing diseases and monitoring the effectiveness of treatments. Initially, disease detection relied heavily on observable physical symptoms and sample analysis. However, with significant technological advancements over the years, the discovery and development of numerous biomarkers have greatly enriched medical diagnostics and treatment options. This evolution has facilitated earlier and more precise diagnoses, improved treatment strategies, and minimized errors, leading to better and more cost-effective healthcare solutions.

The integration of biomarkers into modern medicine spans various functions, from diagnosing conditions to predicting treatment outcomes. They are classified into categories such as molecular, radiographic, histologic, and physiologic biomarkers, each serving unique roles. For example, molecular biomarkers are found in biological samples like blood and cerebrospinal fluid, indicating molecular interactions and biochemical changes. Radiographic biomarkers, derived from imaging studies, non-invasively assess health conditions, such as bone density. Histologic biomarkers reflect biochemical changes in tissues or cells, crucial for diagnosing and staging cancers. Physiologic biomarkers, like blood pressure or heart rate, provide direct insights into bodily functions. These biomarkers enhance disease management through various stages of healthcare, including diagnostic, prognostic, predictive, and monitoring biomarkers, thereby optimizing patient care and treatment strategies.

The growth of the biomarker field is driven by several factors. Innovations in detection technologies, such as next-generation sequencing, high-throughput screening, and bioinformatics, have enhanced the precision and speed of biomarker analysis, essential for timely and accurate diagnoses. The integration of biomarkers with artificial intelligence (AI) and big data analytics enables sophisticated data analysis, improving disease pattern prediction and treatment outcomes. In the pharmaceutical industry, biomarkers streamline drug development processes and personalize drug therapies, reducing clinical trial time and costs. Advanced diagnostic platforms that leverage biomarkers offer comprehensive health assessments, enhancing their practical utility in clinical settings. Additionally, rising health awareness and preventive medicine trends influence biomarker adoption, as consumers seek personalized healthcare solutions. Increased consumer participation in healthcare decisions and supportive regulatory frameworks further drive the use of biomarker-based tests and therapies. The expansion of insurance coverage for biomarker tests makes these advanced diagnostics more accessible, embedding biomarkers into routine medical practice and advancing modern medical diagnostics and therapeutic strategies.

Select Competitors (Total 282 Featured) -

  • Abbott Molecular, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Epigenomics AG
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • QIAGEN NV
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Biomarkers - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growth of Biomarker-Based Diagnostics and Companion Diagnostics
    • Advancements in Genomics and Proteomics Technologies
    • Rising Adoption of Biomarkers in Drug Development and Clinical Trials
    • Impact of COVID-19 Pandemic on Biomarker Research and Development
    • Government Regulations and Standards for Biomarker Validation and Approval
    • Expansion of Biomarker Applications in Oncology and Chronic Diseases
    • Development of Liquid Biopsy and Non-Invasive Biomarker Technologies
    • Consumer Preferences for Early Detection and Preventive Healthcare
    • Role of Biomarkers in Enhancing Clinical Decision-Making
    • Market Penetration of Digital Health and Biomarker Integration
    • Influence of Artificial Intelligence and Machine Learning on Biomarker Discovery
    • Growth of Biomarker-Based Research in Neurological Disorders
    • Challenges Related to Biomarker Validation and Clinical Utility
    • Emerging Markets and Growth Opportunities in Developing Regions
    • Future Trends and Innovations in Biomarker Technologies and Applications
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Safety by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Efficacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Efficacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Efficacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Validation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Immunological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Immunological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Immunological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 36: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Personalized Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Personalized Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 39: World 16-Year Perspective for Personalized Medicines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 40: World Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • JAPAN
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • CHINA
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: China 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • EUROPE
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • FRANCE
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: France 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • GERMANY
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • INDIA
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: India 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • AFRICA
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030

IV. COMPETITION